Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A lncRNA-mediated metabolic rewiring of cell senescence.

Cell reports·2025
Same author

The lncRNA DUBR is regulated by CTCF and coordinates chromatin landscape and gene expression in hematopoietic cells.

Nucleic acids research·2025
Same author

Author Correction: Uncovering functional lncRNAs by scRNA-seq with ELATUS.

Nature communications·2025
Same author

Uncovering functional lncRNAs by scRNA-seq with ELATUS.

Nature communications·2024
Same author

Novel protocol for the transcriptomic analysis of endothelial extracellular vesicles in atherosclerosis.

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2024
Same author

YTHDC1 m<sup>6</sup>A-dependent and m<sup>6</sup>A-independent functions converge to preserve the DNA damage response.

The EMBO journal·2024

関連する実験動画

Updated: Jun 14, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

腫瘍 を 抑制 する"逆 強化 剤"

Francesco P Marchese1, Maite Huarte1

  • 1University of Navarra, Center for Applied Medical Research (CIMA), Pamplona 31008, Spain; Institute of Health Research of Navarra (IdiSNA), Pamplona 31008, Spain.

Cell
|June 2, 2018
PubMed
まとめ

研究者はMYC遺伝子発現を 制御する新しいメカニズムを発見しました PVT1遺伝子の内にあるDNA要素は,プロモーターとエンハンスターの競争相手として作用し,腫瘍抑制剤として機能することが示唆される.

科学分野:

  • 癌 生物学
  • ゲノミクス
  • 分子生物学

背景:

  • がんにおけるノンコーディングゲノムの役割はますます認識されています.
  • MYC遺伝子の発現は,がんの発達と進行において極めて重要です.

研究 の 目的:

  • MYC発現のための新しい規制メカニズムを明らかにする.
  • PVT1遺伝子内の特定のDNA要素の機能を調査する.

主な方法:

  • 遺伝子調節の分析
  • プロモーターとエンハンスターの相互作用を調査する.
  • DNA要素の機能的研究

主要な成果:

  • PVT1遺伝子内のDNA要素がMYC発現を調節する.
  • この要素は プロモーター・エンハンスター・コンピッタとして機能する.
  • 腫瘍抑制剤としての可能性を示している.

結論:

  • PVT1遺伝子プロモーター配列を含むMYC調節のための新しいメカニズムが特定されました.
  • この規制要素は プロモーター・エンハンスター・コンピッタとして機能する.

さらに関連する動画

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

関連する実験動画

Last Updated: Jun 14, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

  • このDNA要素の潜在的腫瘍抑制作用が示唆されています.